US EditionPublished • loading... • Updated
AstraZeneca invests an extra $136M in Qingdao aerosol drug plant
Summary by Digital Phablet
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
AstraZeneca invests an extra $136M in Qingdao aerosol drug plant
UK-Swedish pharmaceutical leader AstraZeneca announced plans to invest an additional $136 million in its aerosol treatment manufacturing facility located in Qingdao, marking the third round of investment in this site. The company will expand its production capabilities for medications targeting asthma and chronic obstructive pulmonary disease (COPD) in Qingdao. This expansion was revealed yesterday, following a deal signed with the Qingdao High-…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
